|
Growth rate and site of pulmonary metastasis to predict lung relapse and overall survival in patients affected by bone and soft tissue sarcomas (B-STS). |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - PharmaMar |
| |
|
Travel, Accommodations, Expenses - PharmaMar |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Speakers' Bureau - PharmaMar |
| |
|
Honoraria - Bayer; Eisai; GlaxoSmithKline; GlaxoSmithKline; Lilly; Merck Serono; Novartis; Pfizer; Pfizer; PharmaMar |
Consulting or Advisory Role - Bayer; Eisai; PharmaMar |
Speakers' Bureau - GlaxoSmithKline; GlaxoSmithKline |
Research Funding - PharmaMar (Inst) |
Travel, Accommodations, Expenses - PharmaMar; tesaro |